Rathbones Group PLC Has $390.45 Million Stock Position in Abbott Laboratories $ABT

Posted by Stanley Muller on May 21st, 2026

Rathbones Group PLC raised its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 3.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,116,386 shares of the healthcare product maker’s stock after purchasing an additional 107,648 shares during the quarter. Abbott Laboratories accounts for about 1.5% of Rathbones Group PLC’s portfolio, making the stock its 14th biggest position. Rathbones Group PLC’s holdings in Abbott Laboratories were worth $390,452,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Little House Capital LLC raised its stake in shares of Abbott Laboratories by 20.0% in the fourth quarter. Little House Capital LLC now owns 9,113 shares of the healthcare product maker’s stock worth $1,142,000 after purchasing an additional 1,520 shares during the last quarter. IFP Advisors Inc lifted its holdings in Abbott Laboratories by 176.7% during the fourth quarter. IFP Advisors Inc now owns 56,041 shares of the healthcare product maker’s stock worth $7,021,000 after acquiring an additional 35,785 shares during the period. Midwest Professional Planners LTD. grew its stake in Abbott Laboratories by 7.6% in the 4th quarter. Midwest Professional Planners LTD. now owns 16,197 shares of the healthcare product maker’s stock valued at $2,029,000 after purchasing an additional 1,145 shares during the period. Banque Cantonale Vaudoise grew its stake in Abbott Laboratories by 6.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 96,352 shares of the healthcare product maker’s stock valued at $12,071,000 after purchasing an additional 5,753 shares during the period. Finally, Fairtree Asset Management Pty Ltd bought a new position in Abbott Laboratories in the 4th quarter valued at $1,059,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $88.38 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The business has a fifty day moving average price of $97.65 and a 200-day moving average price of $112.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market capitalization of $153.93 billion, a P/E ratio of 24.76, a PEG ratio of 1.48 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period last year, the company earned $1.09 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.9%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ABT shares. Stifel Nicolaus reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Mizuho reduced their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Finally, Wells Fargo & Company reduced their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $119.43.

Check Out Our Latest Analysis on ABT

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.